Literature DB >> 2173985

Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay.

S Hildebrandt1, E S Weiner, J L Senecal, G S Noell, W C Earnshaw, N F Rothfield.   

Abstract

Anti-topoisomerase I autoantibodies (anti-topo I, anti-Scl-70) are associated with proximal scleroderma and are of prognostic significance in patients with Raynaud's disease. To establish a highly sensitive and specific system for the detection of anti-topo I, we have investigated sera from 409 patients and controls by Ouchterlony gel diffusion, Western immunoblot on chromosome proteins, and solid-phase enzyme-linked immunosorbent assay (ELISA) with purified topoisomerase I as antigen. The ELISA was more sensitive than the gel diffusion technique and was more specific than the Western immunoblot, while the immunoblot may identify additional autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173985     DOI: 10.1016/0090-1229(90)90114-6

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 2.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

3.  Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases.

Authors:  S A Bell; H Faust; A Schmid; M Meurer
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

4.  Analysis of human antitopoisomerase-I idiotypes.

Authors:  D Vazquez-Abad; V Pascual; M Zanetti; N F Rothfield
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

5.  A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies.

Authors:  S Hildebrandt; G Jäckh; S Weber; H H Peter
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

6.  Fever of unknown origin secondary to type I crescentic glomerulonephritis and anti-SCl 70 antibodies without clinical manifestations of systemic sclerosis.

Authors:  Jorge Vega Stieb; Helmuth Goecke Saavedra; Gonzalo Méndez Olivieri
Journal:  Clin Exp Nephrol       Date:  2008-05-20       Impact factor: 2.801

7.  Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.

Authors:  Kate LaRiviere Homer; Jeffrey Warren; Dmitry Karayev; Puja P Khanna; Amber Young; Vivek Nagaraja; Allan L Metzger; Dinesh Khanna
Journal:  J Clin Rheumatol       Date:  2020-04       Impact factor: 3.902

8.  Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.

Authors:  Katharina Hanke; Cornelia Dähnrich; Claudia S Brückner; Dörte Huscher; Mike Becker; Anthonina Jansen; Wolfgang Meyer; Karl Egerer; Falk Hiepe; Gerd R Burmester; Wolfgang Schlumberger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-02-21       Impact factor: 5.156

9.  The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis.

Authors:  Bochra Jandali; Gloria A Salazar; Marie Hudson; Marvin J Fritzler; Marka A Lyons; Rosa M Estrada-Y-Martin; Julio Charles; Katherine A Terracina; Maureen D Mayes; Shervin Assassi
Journal:  ACR Open Rheumatol       Date:  2022-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.